MiniMed Group (NASDAQ:MMED) Upgraded to Strong-Buy at Benchmark

MiniMed Group (NASDAQ:MMED) was upgraded by stock analysts at Benchmark to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

A number of other equities analysts also recently commented on the company. Bank of America assumed coverage on MiniMed Group in a report on Tuesday, March 31st. They issued a “buy” rating and a $27.00 price objective on the stock. The Goldman Sachs Group initiated coverage on MiniMed Group in a report on Tuesday, March 31st. They set a “buy” rating and a $24.00 price target on the stock. Mizuho initiated coverage on MiniMed Group in a research report on Tuesday, March 31st. They issued an “outperform” rating and a $21.00 price objective for the company. Zacks Research raised MiniMed Group to a “hold” rating in a research report on Thursday, April 9th. Finally, Wells Fargo & Company began coverage on MiniMed Group in a research report on Tuesday, March 31st. They issued an “overweight” rating and a $26.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.25.

MiniMed Group Price Performance

Shares of NASDAQ MMED opened at $11.89 on Monday. MiniMed Group has a twelve month low of $11.10 and a twelve month high of $20.48. The firm has a 50-day simple moving average of $14.42.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.